Sam Fazeli

The OS, on the other hand, is complicated by the different post-progression treatments, for instance, in TBO2 versus Acendo3, which was the Gilead-Tridelby trial.

Given all this, how important do you think OS is in the trial, which may have been driven by post-progression issues, etc.

?

Yeah, agreed.

The one thing I do hear from physicians, though, is the stomatitis issue, which even though, okay, 57% in the, if I'm not wrong, in the TBO2 trial, but majority were low grade.

Even the low grade seems to bother people a little bit, I

Do you think this is something about learning to manage it as we go forward?

Because physicians seem to be always good at dealing with the side effects of cancer drugs to the point that they can.

And then, of course, the competitor drug, Tredelvi, has a different type of side effect, which potentially increases the risk of infections, etc.

So just one quick last comment on this and one last question on Datraway and then we'll move on.

Yeah.

Last question.

What do you think the best partner for a TROP2 ADC is?

I mean, I had a leading question here, but I thought I'd leave that to you to comment.

Yeah.

And of course, my leading question was, is the best combo a PD-1 VEGF or PD-L1 VEGF bispecific?

But I'm going to make a comment and move on to bladder because I'm more interested in your views.

I'm definitely interested in your views on bladder and Matterhorn, Potomac, et cetera.

Sorry, not Matterhorn, Potomac at the conference.

So the problem I have with, everyone's been running around, digging around Harmony 6 trial data.